Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan.
Anticancer Res. 2012 Feb;32(2):491-6.
BACKGROUND/AIM: C-reactive protein (CRP) has been associated with the development of many carcinomas, but the significance of CRP remains unclear for metastatic gastric cancer (MGC).
Sixty one patients who received S-1 plus cisplatin for MGC were retrospectively identified and categorized into two groups depending on the serum CRP level before chemotherapy.
Overall survival was significantly shorter in the CRP≥1.0 group than in the CRP<1.0 group (median, 292 days versus 451 days; p=0.0004). Moreover, progression-free survival was significantly shorter in the CRP≥1.0 group than in the CRP<1.0 group (median, 115 days versus 188 days; p=0.0010). In a multivariate analysis, serum CRP level before chemotherapy was an independent prognostic factor for MGC (hazard ratio 4.20 [95% CI, 1.66 to 10.64] p=0.002).
Serum CRP level before chemotherapy might be a potential prognostic factor for MGC.
背景/目的：C 反应蛋白（CRP）与许多癌症的发生有关，但 CRP 对转移性胃癌（MGC）的意义尚不清楚。
回顾性分析了 61 例接受 S-1 联合顺铂治疗的 MGC 患者，并根据化疗前血清 CRP 水平将其分为两组。
CRP≥1.0 组的总生存期明显短于 CRP<1.0 组（中位生存期 292 天 vs 451 天；p=0.0004）。此外，CRP≥1.0 组的无进展生存期明显短于 CRP<1.0 组（中位生存期 115 天 vs 188 天；p=0.0010）。多因素分析显示，化疗前血清 CRP 水平是 MGC 的独立预后因素（危险比 4.20[95%CI，1.66 至 10.64]，p=0.002）。
化疗前血清 CRP 水平可能是 MGC 的一个潜在预后因素。
